General
Preferred name
ATRACURIUM
Synonyms
ATRACURIUM BESYLATE ()
Atracurium ()
CISATRACURIUM ()
Tracrium ()
51W89 ()
BW-33A ()
Atracurium (besylate) ()
BW 33A, 51W89 ()
WELLCOME 33-A-74 ()
Atracurium besylate preservative free ()
atracurium besilate ()
Besilate d'atracurium ()
Tracrium preservative free ()
BW 33A ()
Atracurium dibesylate ()
NSC-760047 ()
Besilato de atracurio ()
Atracurium ion ()
Atracurium cation ()
P&D ID
PD013187
CAS
64228-81-5
64228-79-1
Tags
available
drug
Approved by
FDA
First approval
1983
Drug indication
Anaesthesia
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation[1][2][3][4][5].
DESCRIPTION
Atracurium (besylate) is a intermediate-duration non-depolarizing neuromuscular blocking agent, delivered by bolus injection in to a vein. It is a complex molecule with potential to exist as multiple stereoisomers.The INN for this drug stipulates the besylate salt, represented in PubChem CID 47320. We show the structure for the parent molecule, with no specified stereochemistry.
(GtoPdb)
DESCRIPTION
Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Atracurium besylate (51W89) is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
23
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
Ki Database
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
58
Molecular Weight
928.51
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
0
Rotatable Bonds
24
Ring Count
6
Aromatic Ring Count
4
cLogP
8.07
TPSA
126.44
Fraction CSP3
0.51
Chiral centers
4.0
Largest ring
6.0
QED
0.04
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
nAChR
MOA
AChR
Pathway
Neuroscience
Membrane Transporter/Ion Channel
Neuronal Signaling
Therapeutic Class
Neuromuscular Nondepolarizing Agents
Source data
